Zacks Research Issues Pessimistic Forecast for AGIO Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Investment analysts at Zacks Research reduced their FY2025 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a note issued to investors on Wednesday, April 9th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings of ($7.56) per share for the year, down from their previous forecast of ($7.55). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q2 2026 earnings at ($1.81) EPS, Q3 2026 earnings at ($1.71) EPS, Q4 2026 earnings at ($1.56) EPS, FY2026 earnings at ($6.95) EPS, Q1 2027 earnings at ($1.52) EPS and FY2027 earnings at ($5.36) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%.

Several other equities research analysts have also recently issued reports on the stock. HC Wainwright started coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They set a “buy” rating and a $58.00 price objective for the company. StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Agios Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $56.57.

Agios Pharmaceuticals Stock Up 3.1 %

NASDAQ AGIO opened at $27.52 on Monday. Agios Pharmaceuticals has a 52 week low of $23.42 and a 52 week high of $62.58. The firm has a 50 day moving average of $31.25 and a two-hundred day moving average of $39.06. The stock has a market capitalization of $1.58 billion, a PE ratio of 2.43 and a beta of 0.83.

Institutional Trading of Agios Pharmaceuticals

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in Agios Pharmaceuticals by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company’s stock valued at $185,045,000 after purchasing an additional 85,339 shares during the period. State Street Corp grew its holdings in shares of Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after buying an additional 216,484 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in Agios Pharmaceuticals in the 4th quarter valued at about $49,290,000. Geode Capital Management LLC raised its stake in Agios Pharmaceuticals by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after acquiring an additional 6,101 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. lifted its position in Agios Pharmaceuticals by 2.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company’s stock worth $35,152,000 after acquiring an additional 25,600 shares during the period.

Insider Activity

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm’s stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the transaction, the director now directly owns 149,220 shares in the company, valued at approximately $3,864,798. This trade represents a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 4.93% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.